Actuate Therapeutics, Inc. Common stock ACTU
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -93.96%
- 1 year
- -94.24%
- Market cap
- 20.34M
- EPS (ttm)
- -0.94
- Shares out
- 19.53M
- YTD return
- -93.96%
- 1-year return
- -94.24%
- Volume
- 303.53K
- Avg volume
- 415.80K
- Open
- 0.36
- Previous close
- 0.35
- Day's range
- 0.341 – 0.38
- 52-week range
- 0.33 – 7.90
2Y -8.4028 (-95.81%)
Key statistics
- Enterprise value
- 268.98M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 351.71K
- Total debt
- 6.90M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 8.35
- 200-day average
- 8.07
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- actuatetherapeutics.com
News
Actuate Therapeutics To Present New Clinical Data Of Oral Elraglusib At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026 
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings 
Actuate Therapeutics Prices ~$11M Offering Of 30,986M Common Shares, Warrants At $0.71 Per Unit 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on ACTU — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 0.71% | 139,511 | 1.05M | Sep 29, 2024 |
| Long Corridor Asset Management Ltd | 0.64% | 125,000 | 941.25K | Sep 29, 2024 |
| Royal Bank of Canada | 0.18% | 35,300 | 265.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.14% | 27,893 | 210.03K | Sep 29, 2024 |
| Northwestern University | 0.14% | 27,778 | 209.17K | Sep 29, 2024 |
| KG&L Capital Management,LLC | 0.06% | 12,000 | 90.36K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.08% | 16,158 | 121.67K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 5,492 | 41.35K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.02% | 3,852 | 29.00K | Oct 30, 2024 |